3839-19-8

Basic information

• Product Name: 4-CYANO-1-NAPHTHOIC ACID
• Synonyms: 4-CYANO-1-NAPHTHOIC ACID;4-Cyano-1-Naphthoic Acid 4cyano1naphthoic acid
• CAS NO: 3839-19-8
• Molecular Formula: C₁₂H₇NO₂
• Molecular Weight: 197.19
• Mol File: 3839-19-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 445.682 °C at 760 mmHg
• Flash Point: 223.341 °C
• Appearance: /
• Density: 1.36 g/cm³
• CAS DataBase Reference: 4-CYANO-1-NAPHTHOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANO-1-NAPHTHOIC ACID(3839-19-8)
• EPA Substance Registry System: 4-CYANO-1-NAPHTHOIC ACID(3839-19-8)

Safety Data

• Hazardous Substances Data: 3839-19-8(Hazardous Substances Data)

Usage

General Description

4-CYANO-1-NAPHTHOIC ACID is a chemical compound with the molecular formula C13H9NO2. It is a naphthoic acid derivative with a cyano group attached at the 4-position of the naphthalene ring. 4-CYANO-1-NAPHTHOIC ACID is a white to yellow crystalline solid with a molecular weight of 211.2 g/mol. It is used as a building block in organic synthesis and as a precursor for the production of various pharmaceuticals and agrochemicals. 4-CYANO-1-NAPHTHOIC ACID is also used as a dye intermediate and in the manufacture of optical brightening agents for textiles and plastics.

Upstream product

• 62855-39-4 4-cyanonaphthalene-1-carboxyaldehyde 
• 39088-39-6 methyl 4-cyano-1-naphthoate 
• 83-53-4 1,4-dibromonaphthalene 
• 16650-55-8 4-bromonaphthalene-1-carboxylic acid 
• 35615-97-5 4-bromo-naphthalene-1-carboxylic acid methyl ester 
• 87700-65-0 4-bromo-1-naphthoic acid chloride 
• 36062-93-8 1-cyano-4-methylnaphthalene 
• 41014-20-4 4-bromomethyl-1-naphthonitrile 

Relevant articles and documents

AMINOETHANOL DERIVATIVES

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

Discovery of novel, orally active dual NK1/NK2 antagonists

Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.